Prescribing of nicotine replacement therapy to cardiovascular disease patients in England
Article first published online: 21 MAR 2012
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction
Volume 107, Issue 7, pages 1341–1348, July 2012
How to Cite
Langley, T. E., Szatkowski, L., McNeill, A., Coleman, T. and Lewis, S. (2012), Prescribing of nicotine replacement therapy to cardiovascular disease patients in England. Addiction, 107: 1341–1348. doi: 10.1111/j.1360-0443.2012.03794.x
- Issue published online: 6 JUN 2012
- Article first published online: 21 MAR 2012
- Accepted manuscript online: 11 JAN 2012 08:07AM EST
- Submitted 15 July 2011; initial review completed 24 November 2011; final version accepted 6 January 2012
- Cardiovascular disease;
- nicotine replacement therapy;
- smoking cessation;
- time series analysis
Aims In November 2005 the indications for nicotine replacement therapy (NRT) were broadened in the United Kingdom, making all forms available to patients with stable cardiovascular disease (CVD). This study aimed to estimate the effects of this change on prescribing of NRT to CVD patients in England.
Design Segmented regression analysis of time series of monthly rates of prescribing of NRT.
Setting A total of 350 general practices in England included in The Health Improvement Network (THIN), a database of UK electronic primary care records.
Participants All adult patients with coronary heart disease (CHD) or stroke registered with a THIN practice in England.
Measurements The number of patients per 100 000 with CHD and stroke that received a prescription for NRT each month between January 2002 and June 2009.
Findings Approximately 1500 per 100 000 smokers with CVD were prescribed NRT per month. Prescribing of NRT to CHD and stroke patients increased until the end of 2005 and subsequently decreased, with no immediate change following the Medicines and Healthcare Regulatory Authority (MHRA) licensing change.
Conclusions Broadening the marketing licence in the United Kingdom for nicotine replacement therapy to allow it to be prescribed to patients with CVD did not increase prescribing rates for this group of patients.